首页> 美国卫生研究院文献>other >Efficacy and Safety of Once-Daily Insulin Degludec/Insulin Aspart versus Insulin Glargine (U100) for 52 Weeks in Insulin-Naïve Patients with Type 2 Diabetes: A Randomized Controlled Trial

【2h】

Efficacy and Safety of Once-Daily Insulin Degludec/Insulin Aspart versus Insulin Glargine (U100) for 52 Weeks in Insulin-Naïve Patients with Type 2 Diabetes: A Randomized Controlled Trial

机译：胰岛素初治的2型糖尿病患者每日一次胰岛素Degludec /门冬胰岛素与胰岛素甘草糖（U100）的疗效和安全性52周：一项随机对照试验

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

PurposeThe efficacy and safety of insulin degludec/insulin aspart (IDegAsp) once daily (OD) compared with insulin glargine U100 (IGlar) OD over 52 weeks in insulin-naïve adults with type 2 diabetes mellitus (T2DM) was investigated.

机译：目的研究52天以上胰岛素初治成人2型糖尿病（T2DM）与地高胰岛素U100（IGlar）OD相比，每日一次地高加德地克胰岛素/门冬胰岛素（IDegAsp）的疗效和安全性。

著录项

期刊名称 other
作者
Ajay Kumar; Edward Franek; Jonathan Wise; Marcus Niemeyer; Henriette Mersebach; Rafael Simó;
展开▼
作者单位

展开▼
年(卷),期 -1(11),10
年度 -1
页码 e0163350
总页数 14
原文格式 PDF
正文语种
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Comparison of the efficacy and safety of once-daily insulin degludec/insulin aspart (IDegAsp) and long-acting second-generation basal insulin (insulin degludec and insulin glargine 300 units/mL) in insulin-na?ve Japanese adults with type 2 diabetes: a pilot, randomized, controlled study [J] . Seiya Shimoda, Wakana Sakamoto, Ayaka Hokamura, Endocrine journal . 2019,第8期

机译：胰岛素-NA've日本成年人患有2型糖尿病的胰岛素-NA've日本成年人的疗效和安全性的疗效和安全性的疗效和安全性和胰岛素的疗效和安全性和胰岛素的疗效和安全性：飞行员，随机，受控研究
2. Superior glycaemic control with once-daily insulin degludec/insulin aspart versus insulin glargine in Japanese adults with type 2 diabetes inadequately controlled with oral drugs: A randomized, controlled phase 3 trial [J] . OnishiY., OnoY., Rab?lR., Diabetes, obesity & metabolism . 2013,第9期

机译：在口服药物控制不充分的日本2型糖尿病成年人中，每天一次使用地格胰岛素/天冬氨酸胰岛素与甘精胰岛素相比，可实现更好的血糖控制：一项随机，对照的3期临床研究
3. The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: A 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes [J] . MeneghiniL., AtkinS.L., GoughS.C.L., Diabetes care . 2013,第4期

机译：与每日一次同时给药的甘精胰岛素和地格列松胰岛素相比，以每天一次的可变给药间隔给予地格列松胰岛素的疗效和安全性：一项为期26周，随机，开放标签，平行组，以治疗为目标的试验在2型糖尿病患者中
4. Insulin Degludec, Insulin Glargine U300, and Other Novel Insulin Formulations [C] . American College of Veterinary Internal Medicine Forum Conference . 2018

机译：胰岛素Degludec，胰岛素甘氨酸U300等新型胰岛素配方
5. A 4-month randomized controlled clinical trial of adjuvant Exenatide or Pramlintide versus insulin alone in pediatric type 1 diabetes mellitus: Effect on glycemic control. [D] . Withycombe, Sarah Elizabeth. 2010

机译：儿科1型糖尿病患者中艾塞那肽或普兰林肽与单独使用胰岛素的4个月随机对照临床试验：对血糖控制的影响。
6. Superior efficacy of insulin degludec/liraglutide versus insulin glargine U100 as add‐on to sodium‐glucose co‐transporter‐2 inhibitor therapy: A randomized clinical trial in people with uncontrolled type 2 diabetes [O] . Athena Philis‐Tsimikas, Liana K. Billings, Robert Busch, -1

机译：地格列克胰岛素/利拉鲁肽优于甘精胰岛素U100作为葡萄糖钠转运蛋白2抑制剂治疗的附加药：一项针对2型糖尿病未控制患者的随机临床试验
7. Efficacy and Safety of Once-Daily Insulin Degludec/Insulin Aspart versus Insulin Glargine (U100) for 52 Weeks in Insulin-Naïve Patients with Type 2 Diabetes: A Randomized Controlled Trial. [O] . Ajay Kumar, Edward Franek, Jonathan Wise, 2016

机译：每日一次胰岛素degludec /门冬胰岛素与胰岛素甘精胰岛素（U100）治疗2型糖尿病胰岛素患者52周的疗效和安全性：随机对照试验。

Efficacy and Safety of Once-Daily Insulin Degludec/Insulin Aspart versus Insulin Glargine (U100) for 52 Weeks in Insulin-Naïve Patients with Type 2 Diabetes: A Randomized Controlled Trial

摘要

著录项

相似文献

相关主题

期刊订阅